Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preventive Healthcare Services01:30

Preventive Healthcare Services

2.3K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.3K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

835
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
835
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

764
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
764
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.6K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine.

Cephalalgia : an international journal of headache·2025
Same author

Practice advisory for intravenous management of headache disorders in hospitalized patients: a review of the evidence and consensus recommendations.

Regional anesthesia and pain medicine·2025
Same author

Insights from 25 years of onabotulinumtoxinA in migraine - mechanisms and management.

Nature reviews. Neurology·2024
Same author

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.

Headache·2024
Same author

Clinical factors associated with day-to-day peak pain severity in individuals with chronic migraine: A cohort study using daily prospective diary data.

Headache·2024
Same author

How early can we treat migraine attacks? A perspective based on prodrome.

Med (New York, N.Y.)·2024

Related Experiment Video

Updated: Apr 5, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.9K

Preventive Migraine Treatment.

Stephen D Silberstein

    Continuum (Minneapolis, Minn.)
    |August 8, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Preventive treatment for migraine is underutilized. Evidence-based guidelines recommend several medications like topiramate and propranolol, alongside lifestyle changes, to improve patient outcomes and reduce side effects.

    More Related Videos

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
    05:49

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

    Published on: November 1, 2024

    1.4K
    Investigating Migraine-Like Behavior Using Light Aversion in Mice
    05:23

    Investigating Migraine-Like Behavior Using Light Aversion in Mice

    Published on: August 11, 2021

    4.6K

    Related Experiment Videos

    Last Updated: Apr 5, 2026

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
    10:39

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

    Published on: June 2, 2014

    18.9K
    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
    05:49

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

    Published on: November 1, 2024

    1.4K
    Investigating Migraine-Like Behavior Using Light Aversion in Mice
    05:23

    Investigating Migraine-Like Behavior Using Light Aversion in Mice

    Published on: August 11, 2021

    4.6K

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Migraine is a common neurological disorder impacting millions globally.
    • Effective preventive strategies are crucial for managing chronic migraine and improving quality of life.

    Purpose of the Study:

    • To review the evidence base for migraine preventive treatments.
    • To summarize recent evidence-based guidelines from major neurological societies.

    Main Methods:

    • Literature review of studies on migraine prophylaxis.
    • Analysis of guidelines from the American Academy of Neurology (AAN) and Canadian Headache Society (CHS).

    Main Results:

    • Strong evidence supports metoprolol, timolol, propranolol, divalproex sodium, sodium valproate, and topiramate for migraine prevention (AAN).
    • CHS strongly recommends topiramate, propranolol, nadolol, metoprolol, amitriptyline, gabapentin, candesartan, Petasites (butterbur), riboflavin, coenzyme Q10, and magnesium citrate.

    Conclusions:

    • Migraine preventive treatments are underutilized in clinical practice.
    • Key principles include improving compliance, minimizing side effects, and optimizing patient outcomes.
    • Treatment selection should consider comorbidities, patient preference, and reproductive status.